Qiagen N.V. (Qiagen) has appointed Stephane Perrey as president of its fully-owned subsidiary QIAGEN KK on January 1, 2009. He follows Kazuo Tokushige, who retired on December 31, 2008, and will lead QIAGEN's further expansion in life sciences and the growing market of molecular diagnostics in Japan. In his new position at QIAGEN, Perrey will assume responsibility for the company's overall business activities in Japan.
Perrey joined the company from Third Wave/Hologic Japan and previously held various positions in the Japanese in-vitro diagnostic industry (especially in infectious diseases segments). He was also involved in the development of the first personalized medicine in-vitro diagnostic product to be approved in Japan. Stephane Perrey holds a Ph.D. in Medical Science from the University of Tokyo and completed his post-doc at Harvard Medical School.
“Stephane brings to QIAGEN a wealth of experience in the Japanese life science and molecular diagnostic industry, and we are pleased to have him on our team”, said Peer M. Schatz, QIAGEN’s chief executive officer. The markets for our products in academic and pharmaceutics research, applied testing and molecular diagnostics are very attractive in Japan and we look forward to growing our already very sizeable presence in this area.”
“Stephane has a strong track record in our customer segments in Japan” said Bernd Uder, Senior Vice President of Global Sales at QIAGEN. “His unique profile combines a strong scientific background with in-depth Japanese business experience. This blend is an excellent formula for our future success in the region.”